Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adeline Vulin

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Drugs|July 23, 2020
Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular DisordersFlavien Bizot, Adeline Vulin, Aurélie Goyenvalle
Drugs|August 5, 2020
Correction to: Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular DisordersFlavien Bizot, Adeline Vulin, Aurélie Goyenvalle
Mutation Research. Reviews in Mutation Research|December 7, 2016
Human epidermal stem cells: Role in adverse skin reactions and carcinogenesis from radiationMichèle T Martin, Adeline Vulin, Jolyon H Hendry
Science (New York, N.Y.)|November 6, 2004
Rescue of dystrophic muscle through U7 snRNA-mediated exon skippingAurélie Goyenvalle, Adeline Vulin, Françoise Fougerousse, et al.
Medecine Sciences : M/S|December 8, 2004
[An opening in Duchenne muscular dystrophy: persistent therapeutic rescue of dystrophin by vectorized antisense mediated exon skipping in mdx mice]Aurélie Goyenvalle, Adeline Vulin, Françoise Fougerousse, et al.
Molecular Therapy. Methods & Clinical Development|April 26, 2021
Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated <i>DMD</i> exon 2 skippingTabatha R Simmons, Tatyana A Vetter, Nianyuan Huang, et al.
Journal of Neuromuscular Diseases|September 5, 2017
Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide ApproachNicolas Wein, Adeline Vulin, Andrew R Findlay, et al.
Neuromuscular Disorders : NMD|September 15, 2015
The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic developmentAdeline Vulin, Nicolas Wein, Tabatha R Simmons, et al.
Human Gene Therapy|April 11, 2009
Immortalized skin fibroblasts expressing conditional MyoD as a renewable and reliable source of converted human muscle cells to assess therapeutic strategies for muscular dystrophies: validation of an exon-skipping approach to restore dystrophin in Duchenne muscular dystrophy cellsSoraya Chaouch, Vincent Mouly, Aurélie Goyenvalle, et al.
International Journal of Radiation Oncology, Biology, Physics|September 8, 2018
Severe PATCHED1 Deficiency in Cancer-Prone Gorlin Patient Cells Results in Intrinsic RadiosensitivityAdeline Vulin, Melissa Sedkaoui, Sandra Moratille, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Drugs|July 23, 2020
Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular DisordersFlavien Bizot, Adeline Vulin, Aurélie Goyenvalle
Drugs|August 5, 2020
Correction to: Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular DisordersFlavien Bizot, Adeline Vulin, Aurélie Goyenvalle
Mutation Research. Reviews in Mutation Research|December 7, 2016
Human epidermal stem cells: Role in adverse skin reactions and carcinogenesis from radiationMichèle T Martin, Adeline Vulin, Jolyon H Hendry
Science (New York, N.Y.)|November 6, 2004
Rescue of dystrophic muscle through U7 snRNA-mediated exon skippingAurélie Goyenvalle, Adeline Vulin, Françoise Fougerousse, et al.
Medecine Sciences : M/S|December 8, 2004
[An opening in Duchenne muscular dystrophy: persistent therapeutic rescue of dystrophin by vectorized antisense mediated exon skipping in mdx mice]Aurélie Goyenvalle, Adeline Vulin, Françoise Fougerousse, et al.
Molecular Therapy. Methods & Clinical Development|April 26, 2021
Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated <i>DMD</i> exon 2 skippingTabatha R Simmons, Tatyana A Vetter, Nianyuan Huang, et al.
Journal of Neuromuscular Diseases|September 5, 2017
Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide ApproachNicolas Wein, Adeline Vulin, Andrew R Findlay, et al.
Neuromuscular Disorders : NMD|September 15, 2015
The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic developmentAdeline Vulin, Nicolas Wein, Tabatha R Simmons, et al.
Human Gene Therapy|April 11, 2009
Immortalized skin fibroblasts expressing conditional MyoD as a renewable and reliable source of converted human muscle cells to assess therapeutic strategies for muscular dystrophies: validation of an exon-skipping approach to restore dystrophin in Duchenne muscular dystrophy cellsSoraya Chaouch, Vincent Mouly, Aurélie Goyenvalle, et al.
International Journal of Radiation Oncology, Biology, Physics|September 8, 2018
Severe PATCHED1 Deficiency in Cancer-Prone Gorlin Patient Cells Results in Intrinsic RadiosensitivityAdeline Vulin, Melissa Sedkaoui, Sandra Moratille, et al.
Pageof 3